Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Diabetes & Endocrinology

Topics

Medicine

Cancer Oncology

Internal Medicine

Endocrinology, Diabetes And Metabolism

Receptor

Show all topics

DOI

10.1016/s2213-8587(21)00120-0